The ongoing pandemic of COVID-19 that started in the Hubei province of China in late December 2019, caused by severe acute respiratory syndrome corona virus-2 (SARS CoV-2). Globally millions affected by the disease so far. The risk of COVID-19 severity and its complications increases with age and other comorbidities. The course of SARS-CoV-2 infection or its related complications has yet to be established in patients with sickle cell disease (SCD), once more evidence is available. It is clear from the available data that the course of COVID-19 in patients with SCD is mild to moderate, seldom severe, and rarely fatal. Herein we report three known cases of SCD with confirmed COVID-19, in whom the course of the disease was mild to moderate and uncomplicated with uneventful recoveries.
Conclusion: Lenalidomide has the advantage of being associated with a much lower risk of peripheral neuropathy than new agents such as bortezomib and thalidomide. In addition, lenalidomide could result in successful ASCT without severe ES through possible immunomodulating effects before ASCT.
Gangrenous cholecystitis (GC) or necrotizing cholecystitis, a grim complication of acute cholecystitis with high morbidity and mortality, commonly seen in old age and patients with concurrent co-morbidities like diabetes. The patients may present with or without signs of acute cholecystitis. Early identification and casespecific intervention are vital to avoid an unwanted outcome. Physicians working as first-level responders such as emergency or primary care should be vigilant to diagnose and to plan a case-based intervention to prevent the potentially worst outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.